SAN DIEGO, Calif., June 14, 2010 – BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced today findings from an exploratory, dose ranging Phase 2a clinical trial not powered for statistical significance. The trial evaluated BCI...